The Scope Fluidics strategy assumes i.a. having at least five new projects in the portfolio, including at least two in the form of special purpose vehicles, by the end of 2025 and completing at least two strategic transactions by the end of 2028, the company announced. Scope Fluidics estimates that after the dividend payment, it will have sufficient funds to develop the capital group within three years.
The strategy is to support the company’s continued development as a platform that generates and sells groundbreaking projects in a repeatable business model.
“Scope Fluidics indicated as strategic goals:
- By the end of 2025, having at least five new projects in the portfolio, including at least two in the form of special purpose vehicles.
- By the end of 2028, completion of at least two strategic transactions.
- In the years 2029-2033, readiness to carry out at least one strategic transaction on an annual average.
As key development vectors determining the implementation of strategic goals, the company indicated further development and completion of the sale of BacterOMIC technology and the creation of an internal organization “Scope Discovery”, responsible for the systemic selection and development of new projects.
“According to the estimates of the Scope Fluidics management board, after the dividend payment for 2022, the company will have approx. PLN 95 million in cash, which is to be sufficient for the development of the Scope Fluidics capital group within three years. At the same time, the company plans to take steps to increase access to financing, preferring non-dilutive sources.
“We accelerate the development of BacterOMIC, using the experience gained. We are launching the ‘Scope Discovery’ organization within Scope Fluidics, whose task will be systemic selection and development of new projects. Our activities focus on shortening the process from selecting a new project to carrying out a strategic transaction. In the coming years, we plan to develop several projects in parallel,” said co-founder, one of the largest shareholders and president of Scope Fluidics, Piotr Garstecki, quoted in the release.
Scope Fluidics was established in 2010 at the Institute of Physical Chemistry of the Polish Academy of Sciences with the aim of creating solutions for medicine based on microfluidic technologies. The company deals with the development of technological projects in the field of diagnostics and health care. In January 2023, the company moved from NewConnect to the main market of the Warsaw Stock Exchange.